At week 36, 42.4 and 27.4% of patients receiving baricitinib 4mg and baricitinib 2mg, respectively, achieved a SALT score of less than or equal to 20 compared with 4.5% of patients receiving placebo.

with severe alopecia areata (AA) treated with once-daily, oral baricitinib 4 mg and 2 mg saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows and eyelashes at Week 36.

Alopecia is an autoimmune disorder that causes non-scarring hair loss on the scalp and body that is experienced by almost 2% ...

Patients with severe to very severe alopecia areata saw hair regrowth with bempikibart treatment within 24 weeks. Hair regrowth seemed to persist after treatment cessation to week 36. ORLANDO ...

TUESDAY, March 18, 2025 (HealthDay News) -- For adolescents with severe alopecia areata (AA), baricitinib is efficacious for ...

Significantly more adolescent patients receiving baricitinib had hair regrowth compared with patients receiving placebo.

2 "Early onset alopecia areata can be more severe ... because they demonstrate that baricitinib can provide significant hair regrowth for adolescents at 36 weeks, a promising early signal of ...

1 Passeron T, et al. Baricitinib provides significant hair regrowth in adolescents with severe alopecia areata: 36-week efficacy and safety results from a Phase 3 randomized, controlled trial.

Oral baricitinib was associated with greater hair regrowth on the scalp, eyebrows and eyelashes compared with placebo in adolescents with severe alopecia areata, data show. Image: Adobe Stock.

with severe alopecia areata (AA) treated with once-daily, oral baricitinib 4 mg and 2 mg saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows and eyelashes at Week 36.